Antiplatelet treatment in peripheral arterial disease: The role of novel antiplatelet agents

Current Pharmaceutical Design

Volumn 22, Issue 29, 2016, Pages 4610-4616

  Klonaris, Chris ^a   Patelis, Nikolaos ^a   Drebes, Anja ^b   Matheiken, Sean ^b   Liakakos, Theodoros ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiplatelet; Novel; PAD; Peripheral arterial disease

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATOPAXAR; CANGRELOR; ELINOGREL; PRASUGREL; TICAGRELOR; VORAPAXAR; ADENOSINE; ADENOSINE PHOSPHATE; IMINE; LACTONE; PYRIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; SULFONAMIDE;

ANTICOAGULANT THERAPY; BLEEDING; DRUG EFFICACY; DRUG INDICATION; HUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES;

ADENOSINE; ADENOSINE MONOPHOSPHATE; IMINES; LACTONES; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PYRIDINES; QUINAZOLINONES; SULFONAMIDES;

EID: 84989238678     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160607065109     Document Type: Review

References (76)

1. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011; 124 (1): 17-23.
2. Andras A, Ferket B. Screening for peripheral arterial disease. Cochrane Database Syst Rev 2014; 4: CD010835.
3. Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e669S-90S.
4. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45 Suppl S: S5-67.
5. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the american association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the american association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; transatlantic inter-society consensus; and vascular disease foundation. Circulation 2006; 113 (11): e463-654.
6. Olin JW, Allie DE, Belkin M, et al. ACCF/AHA/ACR/SCAI/SIR/ SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: a report of the american college of cardiology foundation/american heart association task force on performance measures, the american college of radiology, the society for cardiac angiography and interventions, the society for interventional radiology, the society for vascular medicine, the society for vascu lar nursing, and the society for vascular surgery (writing committee to develop clinical performance measures for peripheral artery disease). Circulation 2010; 122 (24): 2583-618.
7. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA, Investigators C. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009; 30 (2): 192-201.
8. van Kruijsdijk RC, van der Graaf Y, Koffijberg H, et al. Causespecific mortality and years of life lost in patients with different manifestations of vascular disease. Eur J Prev Cardiol 2016; 23 (2): 160-9.
9. Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation 2006; 114 (7): 688-99.
10. Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL, Investigators JL. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010; 31 (21): 2601-13.
11. O’Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 2011; 123 (17): 1843-53.
12. Wiviott SD, Flather MD, O’Donoghue ML, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation 2011; 123 (17): 1854-63.
13. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51 (11): 3061-4.
14. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabetic Med J Br Diabetic Assoc 2007; 24 (5): 486-93.
15. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebocontrolled phase II study. Lancet 2009; 373 (9667): 919-28.
16. Goto S, Yamaguchi T, Ikeda Y, et al. Phase II trial of the novel antiplatelet agent, SCH 530348, in Japanese patients with non-ST segment elevation acute coronary syndromes (NSTE ACS). Eur Heart J 2008; Suppl (29): 829.
17. Shinohara Y, Goto S, Shimizu K, Jensen P. A phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke. Int J Stroke 2008; (3) (Suppl 1): 139.
18. Executive TC, Steering C. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA*CER) trial: study design and rationale. Am Heart 2009; 158 (3): 327-34 e4.
19. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009; 158 (3): 335-41 e3.
20. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366 (1): 20-33.
21. Marino M, Rizzotti D, Leonardi S. Cangrelor: review of the drug and the CHAMPION programme (including PHOENIX). Curr Cardiol Rep 2014; 16 (6): 493.
22. Franchi F, Rollini F, Muniz-Lozano A, Cho JR, Angiolillo DJ. Cangrelor: a review on pharmacology and clinical trial development. Exp Rev Cardiovas Ther 2013; 11 (10): 1279-91.
23. Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361 (24): 2330-41.
24. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361 (24): 2318-29.
25. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368 (14): 1303-13.
26. Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307 (3): 265-74.
27. Leonardi S, Rao SV, Harrington RA, et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y (12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J 2010; 160 (1): 65-72.
28. Tousoulis D, Siasos G, Zaromytidou M, et al. The role of the cytochrome P450 polymorphisms in clopidogrel efficacy and clinical utility. Curr Med Chem 2011; 18 (3): 427-38.
29. Welsh RC, Rao SV, Zeymer U, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circulation Cardiovas Interventions 2012; 5 (3): 336-46.
30. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29 (1): 21-30.
31. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007; 116 (25): 2923-32.
32. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITONTIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371 (9621): 1353-63.
33. Chin CT, Roe MT, Fox KA, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the targeted platelet inhibition to clarify the optimal strategy to medically manage acute coronary syndromes (TRILOGY ACS) trial. Am Heart J 2010; 160 (1): 16-22 e1.
34. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367 (14): 1297-309.
35. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373 (9665): 723-31.
36. Montalescot G, Collet JP, Ecollan P, et al. Effect of prasugrel pretreatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. J Am Coll Cardiol 2014; 64 (24): 2563-71.
37. Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature Clin Practice Cardiovasc Med 2008; 5 (12): 766-80.
38. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11): 1045-57.
39. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120 (25): 2577-85.
40. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010; 121 (10): 1188-99.
41. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324 (7329): 71-86.
42. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC, Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009; 301 (8): 831-41.
43. Banerjee S, Sarode K, Vinas A, Banerjee A, Mohammad A, Brilakis ES. The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization. Curr Opin Cardiol 2015; 30 (5): 525-35.
44. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 2009; 301 (18): 1909-19.
45. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303 (9): 841-8.
46. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840.
47. Collaboration AT. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308 (6921): 81-106.
48. Katsanos K, Spiliopoulos S, Saha P, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: A systematic review and network meta-analysis. PloS One 2015; 10 (8): e0135692.
49. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348 (9038): 1329-39.
50. Agrawal K, Eberhardt RT. Contemporary medical management of peripheral arterial disease: a focus on risk reduction and symptom relief for intermittent claudication. Cardiol Clin 2015; 33 (1): 111-37.
51. Biscetti F, Ferraccioli G, Flex A. New therapeutic effects of cilostazol in patients with ischemic disorders. Curr Vasc Pharmacol 2015; 13 (3): 399-404.
52. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013; 382 (9909): 1981-92.
53. Mehta SR. Cangrelor: a new CHAMPION for percutaneous coronary intervention. Lancet 2013; 382 (9909): 1960-2.
54. Medscape 2014; [Available from: http: //www.medscape.com/viewarticle/820567.
55. USA FDA 2009 [Available from: http: //www.accessdata.fda.gov/drugsatfda_docs/label/2010/022307s002l bl.pdf.
56. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20): 2001-15.
57. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27 (9): 1038-47.
58. USA FDA 2015. [Available from: http: //www.fda.gov/downloads/Drugs/DrugSafety/UCM264220.pdf.
59. Serebruany VL, Tomek A, Pokov AN, Kim MH. Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner? Expert Rev Cardiovasc Therapy 2015; 13 (12): 1333-44.
60. Morici N, Colombo P, Mafrici A, Oreglia JA, Klugmann S, Savonitto S. Prasugrel and ticagrelor: is there a winner? J Cardiovasc Med 2014; 15 (1): 8-18.
61. Oikonomou E, Papageorgiou N, Papaioannou S, et al. Genetic testing and antiplatelet treatment: Still way to go? Int J Cardiol 2015; 187: 63-5.
62. Siasos G, Kioufis S, Oikonomou E, et al. Impact of C34T P2Y12 ADP receptor polymorphism and smoking status on cardiovascular outcome in coronary artery disease patients receiving clopidogrel. Int J Cardiol 2016; 210: 161-3.
63. Siasos G, Kioufis S, Oikonomou E, et al. Impact of C34T P2Y12 genotype on endothelial function and arterial stiffness in patients after percutaneous coronary intervention receiving clopidogrel. Int J Cardiol 2014; 177 (3): 1073-5.
64. Siasos G, Oikonomou E, Zaromitidou M, et al. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy. Atherosclerosis 2015; 242 (1): 102-8.
65. Siasos G, Oikonomou E, Zaromitidou M, et al. High platelet reactivity is associated with vascular function in patients after percutaneous coronary intervention receiving clopidogrel. Int J Cardiol 2014; 177 (1): 192-6.
66. Siasos G, Tousoulis D, Stefanadis C. Multiple mechanisms affect the clopidogrel response. J Am Coll Cardiol 2009; 53 (10): 900-1; author reply 1.
67. Bavishi C, Panwar S, Messerli FH, Bangalore S. Meta-analysis of comparison of the newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol 2015; 116 (5): 809-17.
68. Deharo P, Bassez C, Bonnet G, et al. Prasugrel versus ticagrelor in acute coronary syndrome: a randomized comparison. Int J Cardiol 2013; 170 (2): e21-2.
69. USA FDA 2014. [Available from: http: //www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204886Orig1s 000ODMemo.pdf.
70. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation 2013; 127 (14): 1522-9, 9e1-6.
71. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366 (15): 1404-13.
72. Tantry US, Liu F, Chen G, Gurbel PA. Vorapaxar in the secondary prevention of atherothrombosis. Exp Rev Cardiovas Ther 2015; 13 (12): 1293-305.
73. Clinical Trials. NCT01732822 2015 [Available from: https: //clinicaltrials.gov/ct2/show/NCT01732822.
74. Clinical Trials. NCT02227368 2015 [Available from: https: //clinicaltrials.gov/ct2/show/NCT02227368.
75. Clinical Trials. NCT02660866 2016 [Available from: https: //clinicaltrials.gov/ct2/show/NCT02660866.
76. Clinical Trials. NCT02407314 2016 [Available from: https: //clinicaltrials.gov/ct2/show/NCT02407314.